Quick answer: Non-alcoholic fatty liver disease—now classified as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)—affects more than 35% of urban Indian adults. The greatest danger is that normal ALT and AST enzymes do not rule out liver fibrosis. Progressive fibrosis silently replaces healthy hepatic parenchyma without symptoms until advanced stages. Clinical guidelines recommend using the FIB-4 score (calculated from Age, AST, ALT, and Platelet count) as a primary non-invasive screening tool, followed by secondary assessments like the Enhanced Liver Fibrosis (ELF) score or transient elastography for indeterminate results. [1–3]
Medically reviewed by: Dr. Shantakumar Muruda, MD (Biochemistry), Founder & CEO, QXL Diagnostics Central Laboratory, Bengaluru.
Published: 12 November 2026 · Reading time: approximately 15 minutes.
Specimen requirement: Serum & EDTA Whole Blood · Fasting: 8–10 hours recommended.
At a glance: screening for liver fibrosis#
| Assessment Level | Diagnostic Tool | Primary Purpose & Clinical Action |
|---|---|---|
| First-Line Screening | FIB-4 Score (Age, AST, ALT, Platelets) | Triages patients into Low (<1.30), Indeterminate (1.30–2.67), or High (>2.67) risk of advanced fibrosis (F3–F4). |
| Routine Liver Panel | Liver Function Test (LFT: ALT, AST, Bilirubin, Albumin, GGT, ALP) | Evaluates active hepatocellular inflammation, biliary stasis, and synthetic liver function. |
| Imaging Modality | Abdominal Ultrasound | Detects moderate-to-severe hepatic steatosis (echogenicity); poor sensitivity for early fibrosis. |
| Specialized Blood Biomarker | Enhanced Liver Fibrosis (ELF) Test | Quantifies extracellular matrix turnover (HA, PIIINP, TIMP-1) to resolve indeterminate FIB-4 scores. |
| Physical Elastography | FibroScan / Transient Elastography | Measures liver stiffness in kilopascals (kPa) to quantify structural scarring. |
Key Takeaway: You cannot evaluate fatty liver disease with liver enzymes alone. Up to 50% of individuals with biopsy-proven steatohepatitis (MASH) and significant fibrosis have normal ALT levels. [2]
What is MASLD and MASH?#
In 2023, international multi-society hepatology consensus updated the terminology from NAFLD (Non-Alcoholic Fatty Liver Disease) to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease):
- Steatosis (MASLD): Accumulation of fat within more than 5% of hepatocytes in the presence of at least one metabolic risk factor (overweight/obesity, type 2 diabetes, dyslipidaemia, or hypertension).
- Steatohepatitis (MASH): Fat accumulation accompanied by active hepatocyte ballooning, cell death, and lobular inflammation (formerly NASH).
- Fibrosis Progression: Progressive deposition of fibrous scar tissue graded from Stage F0 (none), F1 (mild), F2 (moderate), F3 (advanced bridging fibrosis), to F4 (cirrhosis).
The FIB-4 Score: How It Works#
The FIB-4 (Fibrosis-4) index is recommended by the American Association for the Study of Liver Diseases (AASLD) and the American Diabetes Association (ADA) as the standard initial risk stratification tool for adults with type 2 diabetes or metabolic syndrome.
The Formula:#
$$\text{FIB-4} = \frac{\text{Age (years)} \times \text{AST (U/L)}}{\text{Platelet Count (}\times 10^9\text{/L)} \times \sqrt{\text{ALT (U/L)}} }$$
Interpreting FIB-4 Results (Ages 35–65):#
- < 1.30 (Low Risk): Has an exceptional 90%–95% negative predictive value for ruling out advanced fibrosis (F3–F4). Patients can be safely managed in primary care with lifestyle modifications and retested in 2 to 3 years.
- 1.30 to 2.67 (Indeterminate Risk): Cannot confirm or exclude fibrosis. Requires secondary non-invasive testing (ELF blood test or transient elastography).
- > 2.67 (High Risk): Significant probability of advanced fibrosis or cirrhosis. Urgent referral to a hepatologist or gastroenterologist for comprehensive clinical evaluation.
Note: For individuals aged >65 years, the lower cutoff is adjusted upward to 2.0 to account for physiological age-related increases.
When Does the ELF Test Add Value?#
The Enhanced Liver Fibrosis (ELF) score is a clinically validated, blood-based in vitro diagnostic test that combines three direct serum markers of extracellular matrix synthesis and degradation:
- Hyaluronic Acid (HA)
- Procollagen III Amino-Terminal Propeptide (PIIINP)
- Tissue Inhibitor of Metalloproteinases-1 (TIMP-1)
Unlike liver enzymes that reflect ongoing acute hepatocyte membrane disruption, ELF directly reflects the active balance of liver matrix remodeling and fibrosis accumulation. It provides high prognostic value for identifying patients likely to progress to liver-related clinical endpoints.
Frequently Asked Questions (FAQs)#
1. Can fatty liver disease be completely reversed?#
Yes. In early stages (steatosis F0–F1 and mild MASH), fatty liver is reversible through sustained lifestyle intervention: 7% to 10% reduction in total body weight, restriction of refined carbohydrates and fructose, aerobic and resistance physical exercise, and control of blood glucose.
2. Can I have advanced liver damage with normal ALT and AST?#
Yes. Serum ALT and AST measure enzyme leakage from acutely damaged liver cell membranes. In indolent, slow-progressing metabolic liver disease, significant fibrosis can accumulate over decades while circulating liver transaminases fluctuate within normal reference limits.
3. What tests are included in a standard Liver Function Test (LFT)?#
A standard LFT includes Total Bilirubin, Direct/Conjugated Bilirubin, AST (SGOT), ALT (SGPT), Alkaline Phosphatase (ALP), Gamma-Glutamyl Transferase (GGT), Total Protein, Serum Albumin, and the Albumin/Globulin (A/G) ratio.
4. How does alcohol affect this test?#
MASLD specifically applies to individuals who consume little or no alcohol (<20 g/day for women, <30 g/day for men). Significant alcohol consumption introduces alcoholic liver disease or dual-etiology steatotic liver disease (MetALD).
5. Where can I get tested in Bengaluru?#
QXL Diagnostics provides comprehensive liver function testing, automated FIB-4 calculation, and metabolic profiling at our NABL-accredited reference laboratory in Kengeri and Yelahanka North Hub, with temperature-controlled home collection across eligible Bengaluru localities.
References & Guidelines#
- Rinella ME, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986.
- American Association for the Study of Liver Diseases (AASLD). Practice Guidance on the Clinical Assessment and Management of Non-Alcoholic Fatty Liver Disease. Hepatology. 2023.
- American Diabetes Association. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
Medical disclaimer: This article is educational and does not constitute individual medical diagnosis or treatment advice. Consult your physician or hepatologist for personalised management of liver health.
Medical & Laboratory Disclaimer
This clinical article is published solely for patient education and informational purposes. It does not replace personal medical advice, clinical diagnosis, prenatal genetic counselling, or obstetric supervision. Appropriate laboratory investigations must be determined by your treating physician based on your personal health history.
Dr. Shantakumar Muruda, MD (Medical Biochemistry)
Head of Clinical Biochemistry & Quality Management, QXL Diagnostics Bengaluru (NABL Accredited Laboratory MC-6849). Trained Lead Assessor for ISO 15189:2022 medical laboratory standards.
QXL Clinical Editorial Commitment: Every health guide, biomarker explanation, and screening schedule published on this portal undergoes rigorous clinical review by qualified MD pathologists and biochemists to ensure adherence to peer-reviewed evidence (ACOG, WHO, ICMR) and laboratory diagnostic accuracy.